When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Last reviewed: 14 Mar 2025
Last updated: 10 Nov 2022

Summary

Definition

History and exam

Key diagnostic factors

  • presence of risk factors
  • muscle weakness
  • paraesthesia
  • back/leg pain
  • respiratory distress
  • speech problems
  • areflexia/hyporeflexia
  • facial weakness
  • bulbar dysfunction causing oropharyngeal weakness
  • extra-ocular muscle weakness
  • facial droop
  • diplopia
  • dysarthria
  • dysphagia
  • dysautonomia
  • pupillary dysfunction
  • ophthalmoplegia

Other diagnostic factors

  • ptosis
  • altered level of consciousness
  • ataxia

Risk factors

  • preceding viral illness
  • preceding bacterial infection
  • preceding mosquito-borne viral infection
  • hepatitis E infection
  • immunisation
  • cancer and lymphoma
  • older age
  • HIV infection
  • COVID-19 infection
  • male

Diagnostic investigations

1st investigations to order

  • nerve conduction studies
  • lumbar puncture
  • LFTs
  • spirometry

Investigations to consider

  • anti-ganglioside antibody
  • serology
  • stool culture
  • HIV antibodies
  • spinal MRI
  • Borrelia burgdorferi serology
  • cerebrospinal fluid (CSF) meningococcal polymerase chain reaction
  • CSF cytology
  • CSF angiotensin-converting enzyme
  • chest x-ray
  • CSF VDRL
  • CSF West Nile polymerase chain reaction

Emerging tests

  • ultrasound imaging of peripheral nerves

Treatment algorithm

Contributors

Authors

Saiju Jacob, MD, DPhil, MRCP (UK), FRCP (Lon)

Consultant Neurologist

Queen Elizabeth Neurosciences Centre

University Hospital Birmingham

Birmingham

UK

Disclosures

SJ has served as an international advisory board member for Alexion, Alnylam, ArgenX, Regeneron, Immunovant, and UCB pharmaceuticals. He is currently an expert panel member of the Myasthenia Gravis consortium for ArgenX, and has received speaker fees from Terumo BCT and Eisai.

Acknowledgements

Dr Saiju Jacob would like to gratefully acknowledge Dr John B. Winer, Dr Michael T. Torbey, Dr Dhruvil J. Pandya, and Dr Prem A. Kandiah, previous contributors to this topic.

Disclosures

JBW, MTT, DJP, and PAK declare that they have no competing interests.

Peer reviewers

Cigdem Akman, MD

Division of Pediatric Neurology

Columbia University College of Physicians and Surgeons

New York

NY

Disclosures

CA declares that he has no competing interests.

Robert Hadden, FRCP, PhD

Consultant Neurologist

King's College Hospital

London

UK

Disclosures

RH has been paid by Baxter Healthcare Ltd for membership of its neurology advisory board, and is a co-author of several studies referenced in this topic.

Use of this content is subject to our disclaimer